Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Short Interest Update

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 61,520 shares, an increase of 31.5% from the December 15th total of 46,799 shares. Based on an average daily volume of 55,407 shares, the short-interest ratio is presently 1.1 days. Currently, 0.8% of the shares of the stock are sold short. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 55,407 shares, the short-interest ratio is presently 1.1 days.

Analysts Set New Price Targets

Several research firms recently commented on BNR. Wall Street Zen upgraded Burning Rock Biotech from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BNR. Crcm LP lifted its position in Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares in the last quarter. Prospera Financial Services Inc bought a new position in shares of Burning Rock Biotech in the third quarter worth about $214,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Burning Rock Biotech in the third quarter worth about $26,000. 30.03% of the stock is owned by institutional investors.

Burning Rock Biotech Trading Down 3.9%

BNR stock opened at $32.01 on Monday. The business has a fifty day moving average price of $19.64 and a 200 day moving average price of $12.21. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91. Burning Rock Biotech has a fifty-two week low of $2.18 and a fifty-two week high of $34.79. The stock has a market capitalization of $344.43 million, a price-to-earnings ratio of -19.28 and a beta of 1.25.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.